Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunotherapy for Recurrent Urinary Tract Infections: Effects of an Escherichia coli Extract

Immunotherapy for Recurrent Urinary Tract Infections: Effects of an Escherichia coli Extract The burden of urinary tract infections (UTIs) is high in both industrialized and developing countries. As causative therapies of these frequently recurring infections have substantial limits, preventive measures deserve priority. Among these, immunostimulation with bacterial extracts has been shown to prevent recurrent UTIs and to be very safe. The aim of this review is to focus on the immunostimulating agent OM-89, a biotechnology-derived lyophilized extract from Escherichia coli, a germ frequently responsible for UTIs, and formulated for oral administration. This review will cover its pharmacological effects and its actions in clinical practice with respect to both efficacy and safety. A particular emphasis will be put on clinical trials conducted in children, adults and special patient populations as well as on a survey assessing the effect of OM-89 on the patients’ quality of life. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Karger

Immunotherapy for Recurrent Urinary Tract Infections: Effects of an Escherichia coli Extract

Loading next page...
 
/lp/karger/immunotherapy-for-recurrent-urinary-tract-infections-effects-of-an-7ZAxJRvXLi

References (40)

Publisher
Karger
Copyright
© 2009 S. Karger AG, Basel
ISSN
1661-7649
eISSN
1661-7657
DOI
10.1159/000189674
Publisher site
See Article on Publisher Site

Abstract

The burden of urinary tract infections (UTIs) is high in both industrialized and developing countries. As causative therapies of these frequently recurring infections have substantial limits, preventive measures deserve priority. Among these, immunostimulation with bacterial extracts has been shown to prevent recurrent UTIs and to be very safe. The aim of this review is to focus on the immunostimulating agent OM-89, a biotechnology-derived lyophilized extract from Escherichia coli, a germ frequently responsible for UTIs, and formulated for oral administration. This review will cover its pharmacological effects and its actions in clinical practice with respect to both efficacy and safety. A particular emphasis will be put on clinical trials conducted in children, adults and special patient populations as well as on a survey assessing the effect of OM-89 on the patients’ quality of life.

Journal

Current UrologyKarger

Published: Jan 1, 2009

Keywords: Bacterial extract; Escherichia coli; Immunostimulation; Immunotherapy; OM-89; Urinary tract infections; Uro-Vaxom®

There are no references for this article.